Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC and Nivolumab in Prostate Cancer
NCT02933255Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PROSTVAC-TRICOM and nivolumab in prostate cancer (PCa), sponsored by National Cancer Institute. Started Apr 2017; status: completed.
02
Drugs
PROSTVAC-TRICOMnivolumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02933255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933255.